A retrospective study assessing effect of daclatasvir and asunaprevir combination therapy on circulating lipoproteins and apolipoproteins in patients infected with hepatitis C virus - genotype 1b

Trial Profile

A retrospective study assessing effect of daclatasvir and asunaprevir combination therapy on circulating lipoproteins and apolipoproteins in patients infected with hepatitis C virus - genotype 1b

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2017

At a glance

  • Drugs Asunaprevir/daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top